Related Experiment Videos
ErbB2 pathways in heart and neural diseases.
Alistair N Garratt1, Cemil Ozcelik, Carmen Birchmeier
1Max-Delbrück-Centre for Molecular Medicine, Robert-Rössle-Strasse 10, Postfach 740238, 13092 Berlin, Germany.
Trends in Cardiovascular Medicine
|February 15, 2003
Summary
The proto-oncogene ErbB2 is crucial for normal heart function and its loss can lead to dilated cardiomyopathy. This finding is relevant to understanding chemotherapy side effects like heart failure in patients treated with trastuzumab.
Area of Science:
- Oncology
- Cardiology
- Molecular Biology
Background:
- The proto-oncogene ErbB2 (HER2) is a receptor tyrosine kinase overexpressed in human tumors and targeted by trastuzumab therapy.
- ErbB2 functions as a coreceptor, forming heteromers with other ErbB family members (ErbB4, ErbB3, EGF receptor) to transduce signals.
- ErbB2/ErbB4 and ErbB2/ErbB3 heteromers are vital for neuregulin-1 signaling in the heart and peripheral nervous system.
Purpose of the Study:
- To investigate the role of ErbB2 in normal heart physiology.
- To determine the consequences of ErbB2 loss in cardiomyocytes.
- To establish a mouse model for trastuzumab-induced cardiotoxicity.
Main Methods:
- Tissue-specific mutation of ErbB2 in cardiomyocytes of mice.
- Analysis of cardiac physiology and function in conditional ErbB2 mutant mice.
- Evaluation of ErbB2's role in differentiated myocardium.
Main Results:
- Loss of cardiac ErbB2 function in adult mice leads to dilated cardiomyopathy.
- ErbB2 is essential for normal heart physiology beyond development.
- Conditional ErbB2 mutant mice exhibit cardiomyopathy and heart failure, mirroring trastuzumab side effects.
Conclusions:
- ErbB2 plays a critical role in maintaining adult heart function.
- Cardiac ErbB2 deficiency results in dilated cardiomyopathy and heart failure.
- Conditional ErbB2 mutant mice serve as a relevant model for trastuzumab-induced cardiotoxicity.